135 filings
Page 2 of 7
6-K
us3m15gbh4icy 9r
16 May 23
Current report (foreign)
4:01pm
6-K
ydxcev
4 May 23
Silence Therapeutics Achieves $10 Million Milestone Payment from AstraZeneca Collaboration
7:41am
6-K
ldt54kl7zuptdp
1 May 23
Current report (foreign)
7:31am
6-K
ffk31rg6ws4il v39ugb
27 Apr 23
Current report (foreign)
4:31pm
6-K
f6d4su3sloywg
28 Mar 23
Silence Therapeutics Appoints Dr. Steven Romano as Incoming Chief Medical Officer and Head of Research and Development
8:00am
SC 13G/A
wr2j9sjdx0kr65jg
14 Feb 23
Silence Therapeutics / TCG Crossover GP I ownership change
2:23pm
SC 13G/A
lm7qtny
14 Feb 23
Silence Therapeutics / Lombard Odier Asset Management ownership change
10:45am
SC 13G/A
32gevian8ahc1jxhaux5
8 Feb 23
Silence Therapeutics / GOLDMAN SACHS ownership change
3:09pm
6-K
247u4icck9jk3f
12 Jan 23
Silence Therapeutics Provides SLN360 and SLN124 Clinical Program Updates
4:30pm
6-K
w2b5j56
10 Nov 22
Current report (foreign)
8:30am
6-K
j7n08
7 Nov 22
Assessment showed participants who received a single dose of SLN360 maintained median reductions over 80% over a five-month period
8:30am
SC 13D/A
zl9haao
20 Oct 22
Silence Therapeutics / Griffiths Richard Ian ownership change
4:01pm
6-K
wwx fz05szy
29 Sep 22
Silence Therapeutics Announces Preliminary Single Dose Results from SLN124 Phase 1 Study in Patients with Thalassemia
8:00am
SC 13G
crh yhfr7evudt5pn
22 Aug 22
Silence Therapeutics / Deep Track Capital ownership change
4:13pm
SC 13G
axxcz9
19 Aug 22
Silence Therapeutics / TCG Crossover Management ownership change
4:30pm
6-K
j7624
16 Aug 22
Current report (foreign)
4:43pm
424B5
8wefgbl78 5rz8
12 Aug 22
Prospectus supplement for primary offering
1:32pm
6-K
bnnmx078
12 Aug 22
Silence Therapeutics Announces Pricing of Underwritten Offering
6:07am
6-K
hzrrtl
11 Aug 22
6-K Q2 2022 Quarterly Results
5:02pm